Menu

USC President Steps Down in Wake of Gynecologist Scandal

An uproar over the university’s handling of sexual misconduct accusations led to C.L. Max Nikias’s resignation.  

May 29, 2018
Sukanya Charuchandra

C.L. Max NikiasFLICKR, DANIEL HINTON FOR DEPARTMENT OF DEFENSEFollowing a backlash over alleged sexual misconduct by a gynecologist at the school health center, C.L. Max Nikias, president of the University of Southern California (USC), stepped down late last week (May 25).

“We have heard the message that something is broken and that urgent and profound actions are needed,” Rick Caruso, a member of the USC Board of Trustees, says in a statement.

Nikias has been in office since 2010, leading the Los Angeles-based university through a period of enormous growth as it benefitted from a $6 billion donation. However, over the past few years, a series of scandals have gripped the establishment. The university’s response to the allegations against George Tyndall, the campus gynecologist for nearly 30 years, was the final nail in the coffin for Nikias’s tenure, according to The New York Times.

Following several complaints from students and staff spanning decades and an ensuing investigation that found Tyndall ’s behavior constituted sexual harassment, he was offered money to resign. Several women have filed lawsuits against Tyndall, according to USA Today, and reporting by the Los Angeles Times has sparked criticism from students, alumni, and faculty over the past few weeks. A letter asking Nikias to resign had garnered almost 500 signatures from faculty by Friday.

“We’re at a real crossroads for the university and this is the first step in starting over,” Ariela Gross, a law professor who led the faculty effort, tells The New York Times.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.